Lysyl oxidases regulate fibrillar collagen remodelling in idiopathic pulmonary fibrosis

Autor: Eric S. White, Janette K. Burgess, Delphine Sicard, Alen Faiz, Gavin Tjin, Daniel J. Tschumperlin, Eleanor P.W. Kable, Annabelle Mahar
Přispěvatelé: Groningen Research Institute for Asthma and COPD (GRIAC), Restoring Organ Function by Means of Regenerative Medicine (REGENERATE)
Jazyk: angličtina
Rok vydání: 2017
Předmět:
0301 basic medicine
MYOFIBROBLAST
Fibrillar Collagens
Medicine (miscellaneous)
lcsh:Medicine
FORCE MICROSCOPE
NINTEDANIB
Extracellular matrix
Protein-Lysine 6-Oxidase
Idiopathic pulmonary fibrosis
Immunology and Microbiology (miscellaneous)
Fibrosis
Transforming Growth Factor beta
Lung
LOXL2
biology
Chemistry
Hydrogels
Anatomy
respiratory system
Extracellular Matrix
3. Good health
medicine.anatomical_structure
06 Biological Sciences
11 Medical and Health Sciences

TRIAL
Collagen
Myofibroblast
Research Article
lcsh:RB1-214
EXPRESSION
FIBROBLASTS
MIGRATION
Neuroscience (miscellaneous)
Lysyl oxidase
General Biochemistry
Genetics and Molecular Biology

Collagen Type I
03 medical and health sciences
medicine
lcsh:Pathology
EXTRACELLULAR-MATRIX
Humans
2ND-HARMONIC GENERATION
lcsh:R
Correction
Transforming growth factor beta
Second harmonic generation
medicine.disease
Idiopathic Pulmonary Fibrosis
respiratory tract diseases
030104 developmental biology
Case-Control Studies
Cancer research
biology.protein
LUNG
Developmental Biology
Zdroj: Disease models & mechanisms, 10(11), 1301-1312. COMPANY OF BIOLOGISTS LTD
Disease Models & Mechanisms
Disease Models & Mechanisms, Vol 10, Iss 11, Pp 1301-1312 (2017)
ISSN: 1754-8403
Popis: Idiopathic pulmonary fibrosis (IPF) is a progressive scarring disease of the lung with few effective therapeutic options. Structural remodelling of the extracellular matrix [i.e. collagen cross-linking mediated by the lysyl oxidase (LO) family of enzymes (LOX, LOXL1-4)] might contribute to disease pathogenesis and represent a therapeutic target. This study aimed to further our understanding of the mechanisms by which LO inhibitors might improve lung fibrosis. Lung tissues from IPF and non-IPF subjects were examined for collagen structure (second harmonic generation imaging) and LO gene (microarray analysis) and protein (immunohistochemistry and western blotting) levels. Functional effects (collagen structure and tissue stiffness using atomic force microscopy) of LO inhibitors on collagen remodelling were examined in two models, collagen hydrogels and decellularized human lung matrices. LOXL1/LOXL2 gene expression and protein levels were increased in IPF versus non-IPF. Increased collagen fibril thickness in IPF versus non-IPF lung tissues correlated with increased LOXL1/LOXL2, and decreased LOX, protein expression. β-Aminoproprionitrile (β-APN; pan-LO inhibitor) but not Compound A (LOXL2-specific inhibitor) interfered with transforming growth factor-β-induced collagen remodelling in both models. The β-APN treatment group was tested further, and β-APN was found to interfere with stiffening in the decellularized matrix model. LOXL1 activity might drive collagen remodelling in IPF lungs. The interrelationship between collagen structural remodelling and LOs is disrupted in IPF lungs. Inhibition of LO activity alleviates fibrosis by limiting fibrillar collagen cross-linking, thereby potentially impeding the formation of a pathological microenvironment in IPF.
Summary: Transforming growth factor-β-induced collagen remodelling is driven by enhanced lysyl oxidase expression in idiopathic pulmonary fibrosis.
Databáze: OpenAIRE